logo

For the Inventor, By the Inventor

Paris, France

Frédéric Revah

This inventor holds 5 USPTO granted patents. Top assignees: Aventis Pharma S.a., Other. Active years: 2001-2004.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Frédéric Revah. Retrieved from https://idiyas.com/inventor/frandeacutedandeacuteric-revah

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 5

% Patents Active = 100.0

Average Co-Inventor Count = 5.2

ph-index = 3

Forward Citations = 64(Granted Patents)


Location History:

  • Antony, FR (2003)
  • Paris, FR (2001 - 2004)

Company Filing History:

goldMedal3 out of 377 
 
Aventis Pharma S.a.
 patents
silverMedal2 out of 834,601 
Other
 patents

Years Active: 2001-2004

Loading Chart...
5 patents (USPTO):Explore Patents
1. 6723315 - Method for treating amyotrophic lateral sclerosis (2004-04-20),
2. 6685934 - Recombinant adenoviruses coding for basic fibroblast growth factors (BFGF) (2004-02-03),
3. 6632427 - Adenoviral-vector-mediated gene transfer into medullary motor neurons (2003-10-14),
4. 6552003 - Muscle reinnervation and motor axon sprouting by administering DNA sequences encoding NT-3 and CNTF (2003-04-22),
5. 6245330 - Recombinant adenoviruses coding for glial-derived neurotrophic factor (GDNF) (2001-06-12),

Title: Frédéric Revah: Innovator in Neurodegenerative Disease Treatment

Introduction

Frédéric Revah is a prominent inventor based in Paris, France. He has made significant contributions to the field of neurodegenerative diseases, particularly through his innovative patents. With a total of 5 patents, Revah's work focuses on novel methods for treating conditions such as amyotrophic lateral sclerosis.

Latest Patents

One of Revah's latest patents is a method for treating amyotrophic lateral sclerosis. This invention concerns a novel approach to treating motor neuron diseases, specifically through the systemic administration of expression systems of neurotrophic factors. Another significant patent involves recombinant adenoviruses coding for basic fibroblast growth factors (bFGF). This invention includes recombinant adenoviruses that comprise a heterologous DNA sequence coding for bFGF, along with its preparation and uses for the treatment and/or prevention of neurodegenerative diseases.

Career Highlights

Throughout his career, Frédéric Revah has worked with notable companies, including Aventis Pharma S.A. His experience in the pharmaceutical industry has greatly influenced his innovative approaches to treatment.

Collaborations

Revah has collaborated with several professionals in his field, including Jacques Mallet and Françoise Finiels. These collaborations have contributed to the advancement of his research and inventions.

Conclusion

Frédéric Revah's contributions to the treatment of neurodegenerative diseases through his patents highlight his role as an influential inventor. His innovative methods and collaborations continue to pave the way for advancements in medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…